

Full Year 2025 Results & Business Highlights

29 April 2026



Disclaimer

- This presentation, including the oral presentation (together, the “Materials”) has been prepared by the management of Biotallys NV (the “Company”). The Materials must be treated confidentially and may not be distributed, passed on or otherwise disclosed. The Materials serve information purposes only and do not constitute a prospectus or any offer for sale or subscription of, or solicitation or invitation to buy or subscribe for, any securities of the Company. The Company’s business, operations, financial situation and prospects are subject to risks and uncertainties. A description of the most important risks and uncertainties can be found in the Company’s annual report available on its website (www.Biotallys.com)
- This presentation includes market share and industry data, which were obtained by the Company from industry publications, press releases, data published by government agencies, industry reports prepared by consultants and other market data providers and internal surveys. The third party sources the Company has used generally state that the information they contain has been obtained from sources believed to be reliable. Some of these third party sources also state, however, that the accuracy and completeness of such information is not guaranteed and that the projections they contain are based on significant assumptions. As the Company does not have access to the facts and assumptions underlying such market data, or statistical information and economic indicators contained in these third party sources, the Company is unable to verify such information and, while the Company believes it to be reliable, it cannot guarantee its accuracy or completeness.
- In addition, certain information in this document is not based on published data obtained from independent third parties or extrapolations therefrom, but rather is based upon the Company’s best estimates, which are in turn based upon information obtained from trade and business organizations and associations, consultants and other contacts within the industries in which the Company operates, information published by its competitors and its own experience and knowledge of conditions and trends in the markets in which it operates. The Company cannot provide any assurance that any of the assumptions that it has made while compiling this data from third party sources are accurate or correctly reflect its position in the industry and none of its internal estimates have been verified by any independent sources. The Company makes no representation or warranty as to the accuracy or completeness of this information. The Company has not independently verified this information and, while the Company believes it to be reliable, it cannot guarantee its accuracy.
- You are responsible for protecting yourself against viruses and other destructive items. You are accessing the Materials is at your own risk and it is your responsibility to take precautions to ensure that they are free from viruses or other items of a destructive nature.
- The Materials are provided in conjunction with the oral presentation held by the Company and should not be taken out of context.
- Biotallys, its business, prospects and financial position remain exposed and subject to risks and uncertainties. A description of and reference to these risks and uncertainties can be found in the annual report on the consolidated annual accounts published on the company’s website
- The information contained in the Materials is subject to change without prior notice. The presentation of the Materials (or any part hereof) shall not create any implication that there has been no change in the information contained in the Materials since the date hereof or that there has been no change in the business or financial position of the Company or its subsidiary since the date hereof. The Company does not undertake to provide any additional information, update or keep current information contained in the Materials, or to remedy any omissions in or from the Materials and any opinions expressed in the Materials are subject to change without prior notice. The foregoing is in any event without prejudice to the Company’s obligations under applicable law in relation to disclosure.
- The Materials contain certain forward-looking statements, sometimes identified by the words “believes,” “expects,” “predicts,” “intends,” “projects,” “plans,” “estimates,” “aims,” “foresees,” “anticipates,” “targets,” and similar expressions or be indications of dates in the future, which speak only as at the date of the Materials. Such statements reflect current views with respect to future events and are subject to risks and uncertainties. Forward-looking statements are based on current plans, estimates, projections and expectations. These statements are based on certain assumptions that may prove to be erroneous. No representations or warranties, express or implied, are given as to the achievement or reasonableness of, and no reliance should be placed on, such forward-looking statements, including any projections, estimates forecasts or targets contained herein. Furthermore, the potential future organization of Biotallys as presented in the Materials (e.g. through statements as “a potential path forward”, “intended”, “planned”, “focused pipeline”) and the manner in which this can be achieved is still an intention only and has not yet been decided upon by Company (cfr. Press release dated 9 February 2026).
- Nothing in this presentation constitutes an offer of securities for sale in the EEA, the United Kingdom, Switzerland, Japan, the United States or elsewhere. The securities of the Company are not registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) and may not be offered, sold or otherwise transferred within the United States (as such term is defined in Regulation S under the Securities Act) unless registered under the Securities Act or pursuant to an exemption from such registration. There is no intention to register securities of the Company under the Securities Act.
- You acknowledge that all industrial and intellectual property rights to this presentation are and shall remain vested in the Company. By attending this presentation or accessing the Materials you shall not acquire any right, title, license to use, or interest in the presentation or the Materials.
- All of the trademarks, service marks and logos displayed in the Materials, including but not limited to Biotallys, AGROBODY, EVOCA are registered and unregistered trademarks of the Company or one of its affiliates. Except as expressly provided in the Materials, you may not reproduce, display or otherwise use trademarks without first obtaining the Company’s written permission.
- Biotallys and each of their logos are commercial names, trademarks or registered trademarks owned by Biotallys NV.



Carlo Boutton


CEO (interim) &
Chief Scientific Officer



Regulatory inflection achieved with first of its kind protein pesticide registration in USA

Estimated registration timelines per geography

		
EVOCA	2025	2026
EVOCA NG	2029	2029-2030
BioFun-6	2030-31	2034-35

 **EU public consultation now initiated!**



Maximum residue level (MRL) exemption for EVOCA

EPA exempted crops treated with EVOCA from tolerance requirements, highlighting its safety profile



Picture: sample of EVOCA

Focused pipeline maximizes near-term value while preserving platform upside

Program	Target	Market	Global Market Size*	Discovery	Development	Registration	Partnership Agreement
EVOCA 1st Gen	Botrytis, powdery mildew	High-value fruits & vegetables	Pilot product				
EVOCA Next Gen	Botrytis, powdery mildew	High-value fruits & vegetables	\$2.4bn				
BioFun-6	Botrytis, powdery mildew, potential other fungi	High-value fruits & vegetables	\$2.4bn				
BioFun-7	Cercospora spp. (leafspot disease)	Cowpeas and other legumes	<\$300m				Gates Foundation
BioFun-4**	Oomycetes (water mold)	Potatoes / High-value fruits & vegetables	\$2bn				Open to R&D collaborations
BioFun-8**	Alternaria spp.	Fruits & vegetables and specialty crops	\$1.1bn				Open to R&D collaborations
BioIns-2	Key insect pests	Non-disclosed					


* Kynetec & internal estimation; BioFun-6 will replace EVOCA NG in case of successful development; ** Suspension of BioFun-4 and BioFun-8, see press release Biotallys of 9 February 2026.

Strategic refocus and operational streamlining

What Changes

Restructuring & Streamlining

- Refocus organization on highest priority programs
- Streamline organization with new strategy



Quantified Impact

Post-Reset Steady State

- Headcount reduction, including leadership
- Reduced cash burn to end of 2028

Strategic partnership with 21st.BIO

Shift fixed costs to variable via asset-light CMO manufacturing

Distribution partner led go-to-market strategy

Outlook 2026

- Advance EVOCA NG in terms of process development as regulatory work and BioFun-6 with ongoing field trials
- Continue optimizing production and manufacturing plans with 21st.Bio and network of CMO's
- Progress other pipeline programs BioFun-7 and BioIns-2, while opening BioFun-4 and -8 to R&D collaborations with third parties
- Executing our strategic refocus with all stakeholders

Luc Van fraeyenhoven

Chief Financial Officer



FY 2025 key financial highlights

In € thousands	2025	2024
Other operating income	3,043	3,183
Research and development expenses	(13,272)	(10,959)
General and administrative expenses	(5,615)	(5,716)
Operating loss	(15,844)	(13,492)
Loss of the period	(15,759)	(13,188)
Net cash inflow (outflow) of the period	(14,600)	1,068
Cash and cash equivalents	8,038	22,638

Financing and cash runway update

- Current cash runway until end of May 2026
- Biotaly's is in well-advanced negotiations with a number of investors to support the execution of its strategic refocus
- Next to an equity injection, Biotaly's is also exploring other alternative dilutive and non-dilutive financing options

Closing remarks and Q&A



Carlo Boutton
CEO ad interim
Chief Scientific Officer



Luc Van fraeyenhoven
Chief Financial Officer

